An observational study in Breast Cancer, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to female participants aged Up to 100 Years. Per ClinicalTrials.gov, last updated 2018-01-04.
Sponsored by Karolinska Institutet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Breast Neoplasms by Karolinska Institutet — 4 open to participants now, 6 under way, 2 of them phase 3. Breast Neoplasms · Karolinska Institutet.
Among the 19 studies in Breast Neoplasms by Karolinska Institutet, this one is the only one that started in 1977, is the only observational one, and was the 8th registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →4 of the 19 studies in Breast Neoplasms by Karolinska Institutet are open now, in 5 countries. Recruiting first, the newest first:
Karolinska Institutet · Sites in Finland, Korea, Republic of, Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+ · Women only
Karolinska Institutet · Sites in Australia, Finland, Sweden and 1 more country
Ages 18–100
Karolinska Institutet
Ages 40–74 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: Up to 100 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3
First in 1977; this study’s year is marked. 1 started in 1977.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35,002 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Median enrollment 175 across the 18 interventional studies, 35,002 across the 1 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Karolinska Institutet is the lead sponsor of 1,149 studies on the registry; 277 are open to participants now.
1 of the studies in Breast Neoplasms by Karolinska Institutet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06471452Karolinska InstitutetTo Live Better After Breast Cancer Treatment | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Breast Neoplasms by Karolinska Institutet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates \<75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer.
The study population consists of all Swedish women operated for centimeter or subcentimeter breast cancer who are included in the regional breast cancer registries (1977 to 2007) or the national breast cancer registry (2008 onwards).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Endocrine therapy · Radiation: Radiotherapy · Drug: Herceptin · Drug: Chemotherapy · Procedure: Type of breast cancer surgery · Other: Age at diagnosis · Other: Screen detected tumor · Other: Menopausal status at diagnosis · Other: Tumor size · Other: Estrogen receptor (ER) status · Other: Tumor grade · Other: HER2-status · Other: Intrinsic subgroups of breast cancer · Other: Nodal status
Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
Radiotherapy versus no radiotherapy.
Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
Chemotherapy versus no chemotherapy.
Type of surgery (partial mastectomy, mastectomy, other).
Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).
Screening detected tumor (yes, no).
Menopausal status (premenopausal, postmenopausal).
Tumor size (≤5 mm, 6-≤10 mm).
ER-status (positive, negative).
Tumor grade (1, 2, 3).
HER2-status (positive, negative).
Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
N-status (N0, N1).
Breast cancer specific death
Time frame: January 1, 1977 to December 31, 2014
Death from any cause
Time frame: January 1, 1977 to July 30, 2016
Metachronous breast cancer
Ipsilateral or contralateral breast cancer
Time frame: January 1, 1977 to July 30, 2016
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 1977 to primary completion in Dec 2014, 455 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.